Page 43 - 2019_01-Haematologica-web

CNS prophylaxis in DLBCL
in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20-27.
33. Mazloom A, Fowler N, Medeiros LJ, et al. Outcome of patients with diffuse large B- cell lymphoma of the testis by era of treat- ment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma. 2010;51(7): 1217-1224.
34. Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88(1):154-161.
35. Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testic- ular and primary central nervous system lymphomas. Blood. 2016;127(7):869-881.
36. Deng L, Xu-Monette ZY, Loghavi S, et al. Primary testicular diffuse large B-cell lym- phoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016;30(2):361-372.
37. Yao Z, Deng L, Xu-Monette ZY, et al. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2018;32(2):353-363.
38. Laskin JJ, Savage KJ, Voss N, et al. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma. 2005;46(12):1721-1727.
39. Lee GW, Go SI, Kim SH, et al. Clinical out- come and prognosis of patients with pri- mary sinonasal tract diffuse large B-cell lym- phoma treated with rituximab-cyclophos- phamide, doxorubicin, vincristine and pred- nisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma. 2015;56(4): 1020-1026.
40. El-Galaly TC, Cheah CY, Hutchings M, et al. Uterine, but not ovarian, female reproduc- tive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. Br J Haematol. 2016;175(5):876-883.
41. Aviv A, Tadmor T, Polliack A. Primary dif- fuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24(9): 2236-2244.
42. Murawski N, Held G, Ziepert M, et al. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood. 2014;124(5):720-728.
43. Lehners N, Kramer I, Schwarzbich MA, et al. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. Leuk Lymphoma. 2016;57(11):2619-2625.
44. Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2012;103(2):245- 251.
45. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533- 3537.
46. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large
B-cell lymphoma treated in the era of ritux-
imab. J Clin Oncol. 2010;28(20):3360-3365. 47. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective
analysis. Blood. 2014;124(15):2354-2361. 48. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol.
2014;166(6):891-901.
49. Kanungo A, Medeiros LJ, Abruzzo LV, et al.
Lymphoid neoplasms associated with con- current t(14;18) and 8q24/c-MYC transloca- tion generally have a poor prognosis. Mod Pathol. 2006;19(1):25-33.
50. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335-1342.
51. Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182-2188.
52. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression con- tributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lym- phoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20): 4021-4031.
53. Song YS, Lee WW, Lee JS, et al. Prediction of Central nervous system relapse of diffuse large B-cell lymphoma using pretherapeutic [18F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography. Medicine. 2015;94(44):e1978.
54. Lemma SA, Pasanen AK, Haapasaari KM, et al. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study. Eur J Haematol. 2016;96(5):492-501.
55. Lemma SA, Kuusisto M, Haapasaari KM, et al. Integrin alpha 10, CD44, PTEN, cadherin- 11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in dif- fuse large B-cell lymphoma. Carcinogenesis. 2017;38(8):812-820.
56. Glass JP, Melamed M, Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369-1375.
57. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lym- phoma. Blood. 1998;91(4):1178-1184.
58. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regi- men) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284-4289.
59. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cere- brospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140-3146.
60. Baraniskin A, Zaslavska E, Nopel- Dunnebacke S, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous sys- tem lymphoma. Neuro Oncol. 2016;18(3): 361-367.
61. Martinez-Ricarte F, Mayor R, Martinez-Saez E, et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free cir- culating tumor DNA from cerebrospinal fluid. Clin Cancer Res. 2018;24(12):2812- 2819.
62. Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the central nervous sys- tem through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016;34 (20):2404-2415.
63. Hutchings M, Ladetto M, Buske C, et al. ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients. Ann Oncol. 2018;29(8):1687-1700.
64. Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non- Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23(5):1267-1273.
65. Tomita N, Takasaki H, Ishiyama Y, et al. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma follow- ing rituximab plus cyclophosphamide, dox- orubicin, vincristine and prednisone. Leuk Lymphoma. 2015;56(3):725-729.
66. Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015;168 (5):654-662.
67. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90(7): 809-818.
68. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lum- bar injections. N Engl J Med. 1975;293(4): 161-166.
69. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol. 1998;38(2-3):135-140.
70. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue pro- files after ventriculocisternal perfusion. J Pharmacol Exp Ther. 1975;195(1):73-83.
71. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915-1925.
72. Niemann A, Muhlisch J, Fruhwald MC, et al. Therapeutic drug monitoring of methotrex- ate in cerebrospinal fluid after systemic high-dose infusion in children: can the bur- den of intrathecal methotrexate be reduced? Ther Drug Monit. 2010;32(4):467-475.
73. Ferreri AJ, Reni M, Pasini F, et al. A multi- center study of treatment of primary CNS lymphoma. Neurology. 2002;58(10):1513- 1520.
74. Ferreri AJ, Reni M, Foppoli M, et al. High- dose cytarabine plus high-dose methotrex- ate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374 (9700):1512-1520.
75. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-2741.
76. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy
haematologica | 2019; 104(1)
33